1 Min Read
Nov 6 (Reuters) - Prescient Therapeutics Ltd
* U.S. FDA lifted clinical hold placed on Co’s phase 1b trial of PTX- 200 in patients with ovarian cancer Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.